Drug Profile
Research programme: antibacterials - The Medicines Company
Latest Information Update: 17 Jan 2020
Price :
$50
*
At a glance
- Originator Targanta Therapeutics Corporation
- Developer The Medicines Company
- Class Peptides; Small molecules
- Mechanism of Action DNA synthesis inhibitors; DNA-directed RNA polymerase inhibitors; Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pseudomonal infections; Staphylococcal infections; Streptococcal infections
Most Recent Events
- 06 Jan 2020 The Medicines Company has been acquired by Novartis
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pseudomonal-infections in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Staphylococcal-infections in Canada